XCSport体育
About Henlius
Company Profile
XCSport体育:Corporate Culture
Honor
XCSport体育:Board of Directors
XCSport体育:Management Team
Advisory Committee
Product
Marketed Products
Products in R&D
Clinical Trial
Science & Technology
R&D Result
Innovation Centre
Technology Platform
Quality Management
Manufacturing
Collaborations
Investor Relations
Information Disclosure
Corporate Governance
XCSport体育:Financial Reports
XCSport体育:Stock Info
IR Calendar
Investor Presentation
Analyst Coverage
Contact Information
Media
Press Release
Multi-media
XCSport体育:Media Reports
XCSport体育:Media Enquiry
Careers
Talent Philosophy
XCSport体育:Staff Life
Training and Development
Job Opportunities
Contact Us
Contact Information
Customer Message
Privacy
Legal Statement
Compliance
EN
简体
EN
繁體
Home
XCSport体育:About Henlius
XCSport体育:Company Profile
XCSport体育:Corporate Culture
Honor
Board of Directors
Management Team
Advisory Committee
Product
XCSport体育:Marketed Products
XCSport体育:Products in R&D
XCSport体育:Clinical Trial
XCSport体育:Science & Technology
R&D Result
Innovation Centre
XCSport体育:Technology Platform
Quality Management
XCSport体育:Manufacturing
Collaborations
Investor Relations
Information Disclosure
Listing Documents
Announcement & Circulars
Corporate Governance
Financial Reports
Stock Info
XCSport体育:IR Calendar
Investor Presentation
Analyst Coverage
Contact Information
Media
XCSport体育:Press Release
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
Multi-media
Company
Event
Popular Science
Media Reports
XCSport体育:Media Enquiry
Careers
Talent Philosophy
Staff Life
Training and Development
Job Opportunities
XCSport体育:Contact Us
Contact Information
Customer Message
Privacy
Legal Statement
XCSport体育:Compliance
搜索
Be the most trusted biotech company
XCSport体育:Press Release
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
XCSport体育:Multi-media
Company
XCSport体育:Popular Science
XCSport体育:Highlights
Download
Media Reports
XCSport体育:Media Enquiry
2024-02-01
First Subject Dosed for Phase 1 Clinical Trial of Henlius’ Daratumumab Biosimilar HLX15
2024-01-17
Henlius’ Novel Anti-PD-1 mAb HANSIZHUANG (Serplulimab) Approved for the Treatment of ES-SCLC
2024-01-05
First Patient Dosed for MRCT Phase 3 Study on First-Line LS-SCLC of Henlius Anti-PD-1 mAb Serplulimab in the US
1
...
5
6
7
8